Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs Shell PLC (SHEL) Price & Performance

IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs Shell PLC — how do they compare? IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B), while Shell PLC trades at $100.15 (market cap $284.34B). The key difference: Shell PLC is far larger — about 7× IDEXX Laboratories, Inc.'s market cap, and Shell PLC pays a 3.12% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Shell PLC for 90 Days on average.

IDXXSHEL
Market Cap
$40.43B$284.34B
Volume
692,1649,097,469
Sector
HealthEnergy
52-Week High
$766.68$100.20
52-Week Low
$504.70$70.31
Typical Hold Time
46 Days90 Days
Enterprise Value
$41.32B$326.04B
Dividend Yield
—3.12%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.

The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.

Shell PLC

Shell (SHEL) trades at $100.56, up 3.83% today, approaching its 52-week high. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The stock shows bullish technical signals, supported by strong cash flow and a 61.5% analyst buy rating. Key developments include the LNG Canada Phase 2 expansion, doubling export capacity, and new carbon capture deals, highlighting strategic growth in energy transition assets.

Outlook remains positive with valuation metrics like P/E of 11.08 and EV/EBITDA of 4.8 suggesting room for upside toward the $102.53 consensus target. Risks include volatile oil prices and execution challenges in new projects, but robust LNG demand and portfolio optimization provide a solid foundation for investor returns.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IDXX

No sentiment data available yet.

SHEL
2% Buy98% Sell
Avg holding period · 90 Days

Top news

Latest headlines on both assets

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX →

About Shell PLC

Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.

Read more on SHEL →